We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Trends in chronic opioid therapy among survivors of head and neck cancer.
- Authors
Kriplani, Anuja; Lavery, Jessica A.; Mishra, Akriti; Korenstein, Deborah; Lipitz‐Snyderman, Allison N.; Boudreau, Denise M.; Moryl, Natalie; Gillespie, Erin F.; Salz, Talya
- Abstract
Background: Survivors of head and neck cancer (HNC) have increased risk of opioid misuse. Methods: Using Surveillance, Epidemiology and End‐Results‐Medicare data, we matched adults ≥66 years diagnosed with HNC 2008‐2015 with cancer‐free controls. We computed odds ratios (OR) for receipt of chronic opioid therapy (COT, claims for ≥90 consecutive days) for HNC survivors compared to controls each year after matching through 2016. Results: The cohort of HNC survivors declined from 5107 in the first year after diagnosis to 604 in the sixth year after diagnosis. For 5 years, rates of COT among HNC survivors exceeded that of controls. Differences between survivors and controls declined each year (ORs: year 1, 4.36; year 2, 2.60; year 3, 2.18; year 4, 1.85; and year 5, 1.35; all P‐values <.05). Conclusions: Among older HNC survivors, cancer‐associated opioid use in the first years after diagnosis suggests that the benefit of opioids must balance the risk of opioid misuse.
- Subjects
HEAD &; neck cancer; OPIOID abuse; YEAR; MEDICARE Part D; OPIOIDS
- Publication
Head & Neck, 2021, Vol 43, Issue 1, p223
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.26478